Alector advances AL137 toward IND, reports Q2 2026 results

Alector, Inc. reported second quarter 2026 results and business updates on August 6, 2026. Following completion of IND-enabling studies evaluating both subcutaneous and intravenous administration, the company selected AL137 as the lead molecule for its anti-amyloid beta antibody program for Alzheimer's disease, with AL037 retained as a backup candidate.¹ Alector is targeting an IND submission in the first quarter of 2027 and first-in-human dosing in Australia no later than April 2027.¹

AL137 pairs Alector's anti-Aβ antibody targeting pyroglutamate-3 Aβ with the company's Alector Brain Carrier (ABC) platform, according to the release. The company said preclinical data showed a favorable safety profile, with no observed adverse effects and only transient, reversible, non-adverse hematological findings with subcutaneous dosing.¹

On the siRNA side, Alector's lead siRNA program, AL064/AL164, targets tau protein in Alzheimer's disease and other tauopathies; AL064 showed tau mRNA reduction and durable lowering of phospho-Tau 217 in non-human primate brains, and a modified version is advancing into IND-enabling studies as AL164.¹ AL050, an ABC-enabled engineered glucocerebrosidase enzyme replacement therapy, remains in preclinical development for Parkinson's disease.¹

On financials, Alector's cash, cash equivalents, and investments totaled $172.8 million as of June 30, 2026.¹ Management said this is expected to be sufficient to fund operations at least through 2027.¹ The company reported a net loss of $23.0 million, or $0.21 per share, for the quarter, compared with a net loss of $30.5 million, or $0.30 per share, in the same period of 2025.¹